Related Experiment Video
Updated: Sep 19, 2025
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among
Marjorie Argollo1, Yoon K An2, Nahla Azzam3
1Department of Gastroenterology, Federal University of São Paulo, São Paulo, Brazil.
Introduction:
Understanding patient preferences is important for facilitating informed decision-making in managing patients with inflammatory bowel disease (IBD). This study explored the preferences of patients with Crohn's disease (CD) and ulcerative colitis (UC) regarding advanced therapy treatment attributes in five non-Western countries: Argentina, Australia, Brazil, Saudi Arabia and Taiwan.
Methods:
Adult patients with self-reported CD or UC treated for ≥ 6 months participated in this cross-sectional online survey. A discrete choice experiment assessed the relative importance of treatment attributes using conditional logit models. The primary objective was to estimate partworth utilities across the five countries (overall population).
Results:
Overall, 706 patients with CD and UC (n = 353 each) completed the survey (mean age 36.8 and 37.7 years; female 47.9% and 47.6%; mean disease duration 4.5 and 4.6 years, respectively). For patients with CD, the rate of long-term remission on maintenance therapy (LTREM) was the most preferred treatment attribute (32.5%), followed by the rate of 1-year remission (25.7%), routes of administration (RoAs; 24.6%) and risk of serious adverse events (AEs) (11.5%) and mild AEs (5.8%). For patients with UC, the rate of corticosteroid-free remission after 1 year was the most important attribute (30.8%), followed by RoAs (27.4%), rate of mucosal healing after 1 year (16.1%), LTREM (14.9%) and risk of serious AEs (10.0%) and mild AEs (0.8%). Patients in both groups considered abdominal pain as the symptom most impacting their quality of life. Approximately half of the patients (CD 49.3%; UC 50.5%) exposed to advanced therapy indicated that they would have preferred to start advanced therapy earlier.
Conclusion:
Patients with IBD from non-Western countries prioritised advanced treatment attributes such as efficacy outcomes and RoAs, although treatment preferences varied between patients with CD and UC. Shared decision-making between patients and physicians regarding advanced therapy choice and timing should occur throughout the treatment journey.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Assessment of the Gastrointestinal System II: Health Perception Pattern
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...